Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

May 26, 2024

Study Completion Date

May 26, 2024

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.

BIOLOGICAL

Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)

The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.

BIOLOGICAL

Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)

The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.

Trial Locations (1)

Unknown

Henan Center for Diseases Control and Prevention, Zhengzhou

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY